NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors

por Cecchini, Michael, Walther, Zenta, Wei, Wei, Hafez, Navid, Pilat, Mary Jo, Boerner, Scott A., Durecki, Diane E., Eder, Joseph P., Schalper, Kurt A., Chen, Alice P., LoRusso, Patricia
Publicado 2023

Multicenter Phase II Trial of the PARP Inhibitor Olaparib in Recurrent IDH1- and IDH2-mutant Glioma

por Fanucci, Kristina, Pilat, Mary Jo, Shyr, Derek, Shyr, Yu, Boerner, Scott, Li, Jing, Durecki, Diane, Drappatz, Jan, Puduvalli, Vinay, Lieberman, Frank Scott, Gonzalez, Javier, Giglio, Pierre, Ivy, S. Percy, Bindra, Ranjit S., Omuro, Antonio, LoRusso, Patricia
Publicado 2023

Identifying treatment options for BRAF(V600) wild-type metastatic melanoma: A SU2C/MRA genomics-enabled clinical trial

por LoRusso, Patricia M., Sekulic, Aleksandar, Sosman, Jeffrey A., Liang, Winnie S., Carpten, John, Craig, David W., Solit, David B., Bryce, Alan H., Kiefer, Jeffrey A., Aldrich, Jessica, Nasser, Sara, Halperin, Rebecca, Byron, Sara A., Pilat, Mary Jo, Boerner, Scott A., Durecki, Diane, Hendricks, William P. D., Enriquez, Daniel, Izatt, Tyler, Keats, Jonathan, Legendre, Christophe, Markovic, Svetomir N., Weise, Amy, Naveed, Fatima, Schmidt, Jessica, Basu, Gargi D., Sekar, Shobana, Adkins, Jonathan, Tassone, Erica, Sivaprakasam, Karthigayini, Zismann, Victoria, Calvert, Valerie S., Petricoin, Emanuel F., Fecher, Leslie Anne, Lao, Christopher, Eder, J. Paul, Vogelzang, Nicholas J., Perlmutter, Jane, Gorman, Mark, Manica, Barbara, Fox, Lisa, Schork, Nicholas, Zelterman, Daniel, DeVeaux, Michelle, Joseph, Richard W., Cowey, C. Lance, Trent, Jeffrey M.
Publicado 2021